Dr. Ansbert Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996.
Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University. At the German Cancer Research Center, Dr. Gadicke cloned the first cDNAs of HPV16 and 18 in Prof. Harald zur Hausen's group (Nobel Laureate in Physiology or Medicine, 2008). Dr. Gadicke has published in leading scientific publications including Nature and Cell.
He is a member of the Board of Fellows of Harvard Medical School and the MGH Research Advisory Council.
Radius Health, Inc.
Sideris Pharmaceuticals, Inc.
BioMarin Pharmaceuticals, Inc. (NASDAQ:BMRN)
Biovitrum AB (Stockholm:BVT)
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)
Kourion Therapeutics AG (acquired by VIAC)
MediGene AG (Frankfurt:MDG)
Omrix (NASDAQ:OMRI) (acquired by JNJ)
National Venture Capital Association
Pharmasset, Inc. (NASDAQ:VRUS) (acquired by GILD)
Solasia Pharma K.K., Tokyo
Transform (acquired by JNJ)
Verastem, Inc. (NASDAQ:VSTM)
ViaCell (NASDAQ:VIAC) (acquired by PKI)